76.4 F
San Fernando
Tuesday, Sep 26, 2023

FDA panel recommends limits on Amgen anemia drugs

In mixed news for biotech giant Amgen Inc., a Food and Drug Administration panel recommended Thursday that doctors continue to prescribe the company’s lucrative anemia drugs for patients with cancer. But the panel suggested scaling back which patients should be treated based on their type of cancer and the severity of the disease. The recommendations could lead to further sales declines in the company’s blockbuster drug Aranesp. Thousand Oaks-based Amgen makes an identical product that is sold under the name Procrit by Johnson & Johnson. For the full story visit http://www.latimes.com/business/la-fi-amgen14mar14,1,3880329.story

Featured Articles

Related Articles